Literature DB >> 27767089

The effect of oxamflatin on the E-cadherin expression in gastric cancer cell line.

E Faghihloo1, Y Araei2, M Mohammadi3, H Mirzaei4, H R Mohammadi5, T Mokhtari-Azad6.   

Abstract

Gastric cancer is among the leading causes of cancer-related death, and the symptoms are commonly characterized in advanced stages. Histone acetylation is among the most important epigenetic alterations occurring during cancer development. In addition, reduced E-cadherin expression is a major contributor in the process of tumor cell invasion and metastasis. Oxamflatin is a histone deacetylase inhibitor that has been suggested as a promising anti-tumor agent; yet its effect on the viability and invasion of gastric tumor cells is unclear. We aimed to assess the impact of oxamflatin on the viability of gastric tumor cells and expression of E-cadherin as a marker of tumor invasion susceptibility. In this study, MKN-45 cells were treated with 1, 2.5 and 5 mM oxamflatin and followed by MTT assay after 24-48 h of incubation. To determine E-cadherin expression in treated cells, total RNA was extracted and reverse transcribed to complementary DNA, followed by quantitative real-time PCR. MTT results showed that the viability of MKN-45 cells declines with increasing concentrations of oxamflatin. The results of quantitative real-time PCR showed increased expression of E-cadherin following treatment with oxamflatin at the concentration of 2.5 mM compared with 1 mM. The present results showed that oxamflatin can induce E-cadherin expression and also reduce cell viability in the MKN-45 cell line. On the basis of these findings, oxamflatin can be further considered for the prevention of tumor metastasis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27767089     DOI: 10.1038/cgt.2016.52

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  21 in total

Review 1.  Histone acetylation and chromatin remodeling.

Authors:  P D Gregory; K Wagner; W Hörz
Journal:  Exp Cell Res       Date:  2001-05-01       Impact factor: 3.905

2.  Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase.

Authors:  Y B Kim; K H Lee; K Sugita; M Yoshida; S Horinouchi
Journal:  Oncogene       Date:  1999-04-15       Impact factor: 9.867

3.  Apoptosis mechanisms of human gastric cancer cell line MKN-45 infected with human mutant p27.

Authors:  Jin-Shui Zhu; Long Wang; Guo-Qiang Cheng; Qin Li; Zu-Ming Zhu; Li Zhu
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

4.  HDAC Inhibitor Oxamflatin Induces Morphological Changes and has Strong Cytostatic Effects in Ovarian Cancer Cell Lines.

Authors:  Y-L Wang; H-L Liui; R-G Fu; Z-W Wang; H-T Ren; Z-J Dai; Y-Y Jing; Y Li
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

5.  n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells.

Authors:  M G Riggs; R G Whittaker; J R Neumann; V M Ingram
Journal:  Nature       Date:  1977-08-04       Impact factor: 49.962

6.  Valproic acid inhibits prostate cancer cell migration by up-regulating E-cadherin expression.

Authors:  Lei Zhang; Guiying Wang; Lin Wang; Chenlin Song; Xinhua Wang; Jiuhong Kang
Journal:  Pharmazie       Date:  2011-08       Impact factor: 1.267

Review 7.  SiRNA and epigenetic aberrations in ovarian cancer.

Authors:  Hamed Mirzaei; Foad Yazdi; Rasoul Salehi; Hamid Reza Mirzaei
Journal:  J Cancer Res Ther       Date:  2016 Apr-Jun       Impact factor: 1.805

Review 8.  Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies.

Authors:  Reza Salarinia; Amirhossein Sahebkar; Mostafa Peyvandi; Hamid Reza Mirzaei; Mahmoud Reza Jaafari; Maryam Matbou Riahi; Hamed Ebrahimnejad; Javid Sadri Nahand; Jamshid Hadjati; Mobina Ostadi Asrami; Sara Fadaei; Rasoul Salehi; Hamed Mirzaei
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

9.  Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.

Authors:  Melissa J Peart; Kellie M Tainton; Astrid A Ruefli; Anthony E Dear; Karin A Sedelies; Lorraine A O'Reilly; Nigel J Waterhouse; Joseph A Trapani; Ricky W Johnstone
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

10.  Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.

Authors:  Chandra R Tate; Lyndsay V Rhodes; H Chris Segar; Jennifer L Driver; F Nell Pounder; Matthew E Burow; Bridgette M Collins-Burow
Journal:  Breast Cancer Res       Date:  2012-05-21       Impact factor: 6.466

View more
  6 in total

1.  Discovering Biomarkers in Peritoneal Metastasis of Gastric Cancer by Metabolomics.

Authors:  Guoqiang Pan; Yuehan Ma; Jian Suo; Wei Li; Yang Zhang; Shanshan Qin; Yan Jiao; Shaopeng Zhang; Shuang Li; Yuan Kong; Yu Du; Shengnan Gao; Daguang Wang
Journal:  Onco Targets Ther       Date:  2020-07-27       Impact factor: 4.147

2.  MicroRNA-424 regulates cisplatin resistance of gastric cancer by targeting SMURF1 based on GEO database and primary validation in human gastric cancer tissues.

Authors:  Li Lu; Menglin Wu; Yaoheng Lu; Zhicheng Zhao; Tong Liu; Weihua Fu; Weidong Li
Journal:  Onco Targets Ther       Date:  2019-09-17       Impact factor: 4.147

3.  Propofol Suppresses Proliferation, Migration, Invasion And Promotes Apoptosis By Upregulating microRNA-140-5p In Gastric Cancer Cells.

Authors:  Fengbo Zhu; Qiuxia Li; Ying Yang; Liangui Wang; Jing Wang
Journal:  Onco Targets Ther       Date:  2019-11-25       Impact factor: 4.147

4.  Association of levels of metabolites with the safe margin of rectal cancer surgery: a metabolomics study.

Authors:  Shaopeng Zhang; Guoqiang Pan; Zhifeng Liu; Yuan Kong; Daguang Wang
Journal:  BMC Cancer       Date:  2022-10-05       Impact factor: 4.638

5.  Anticancer Effect of Enterocin A-Colicin E1 Fusion Peptide on the Gastric Cancer Cell.

Authors:  Hadis Fathizadeh; Mahmood Saffari; Davoud Esmaeili; Rezvan Moniri; Javad Amini Mahabadi
Journal:  Probiotics Antimicrob Proteins       Date:  2021-06-15       Impact factor: 4.609

6.  Plasma Neurofilament Light Chain May Be a Biomarker for the Inverse Association Between Cancers and Neurodegenerative Diseases.

Authors:  Shunjie Liu; Zhenze Huang; Lijin Zhang; Junhao Pan; Qingfeng Lei; Yangyang Meng; Zhong Li
Journal:  Front Aging Neurosci       Date:  2020-01-29       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.